Navigation Links
Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
Date:1/24/2011

THOUSAND OAKS, Calif. and WOBURN, Mass., Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately held, venture-funded,  biotechnology company headquartered in Woburn, Mass. BioVex is developing OncoVEX(GM-CSF), a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.

Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones.  The transaction has been approved by the boards of directors of each company.  It is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2011.  Following the completion of the transaction, BioVex will become a wholly owned subsidiary of Amgen.  

"OncoVex has demonstrated encouraging anti-tumor activity in clinical studies for the treatment of melanoma and head and neck cancer, and BioVex is currently enrolling patients into pivotal Phase 3 trials in both indications," said Roger M. Perlmutter, M.D., Ph.D., Amgen's executive vice president, Research and Development.  "Amgen is particularly excited about joining with BioVex and its talented staff to focus on advancing this late-stage investigational therapy, with the hope of bringing it to market within the next few years."

"Amgen is ideally positioned to leverage the potential of OncoVEX in multiple solid tumor indications given their impressive oncology franchise and expertise in biologics manufacturing and development," said Philip Astley-Sparke, chi
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
2. Call for Applications: The Amgen Award for Science Teaching Excellence
3. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
4. Amgen to Provide Testimony at FDA Hearing on Biosimilars
5. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
6. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
7. Array BioPharma and Amgen Partner in Type 2 Diabetes
8. Amgen to Present at Lazard Capital Healthcare Conference
9. Amgen Announces Webcast of 2009 Third Quarter Financial Results
10. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014 BCC Research reveals in ... CELLS , the global market for stem cells is ... with a five-year compound annual growth rate (CAGR) of ... Americas with growth projections of $2.2 billion in 2014 ... http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications of ...
(Date:9/15/2014)... Cancer Immunotherapy Market : Immune ... is a new market research report announced by ... types of therapeutics that have become the major ... (which is often called "immuno-oncology") in recent years: ... immunotherapy. , The regular use of immunotherapy ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... Q4 2007 sales increased 78.8% compared to Q4 2006 -- ... Estimated sales for FY ... increased 89.4% compared to FY 2006, NEW YORK, March ... a leading provider in the,nutraceutical industry engaged in the development, ...
... WELLESLEY HILLS, Mass., March 5 Joseph F. Finn, ... ActivBiotics, confirmed,today that the sale of ActivBiotics, proprietary assets ... PM on March 14, 2008. There has been,substantial interest ... 48 bid packages being reviewed by companies, in addition,to ...
... NEW YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... Board of Directors,has elected Jean-Marc Huet senior vice ... In this role, Mr. Huet will be,responsible for ... as the global financial operations of the organization ...
Cached Biology Technology:China Yingxia International Announces Q4 and FY 2007 Estimates 2China Yingxia International Announces Q4 and FY 2007 Estimates 3Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Exxon Valdez spilled 11 million gallons of oil into ... another giant oil spill in the Gulf of Mexico ... Journal of Consumer Research , news coverage of ... of catalyzing changes in the way fossil fuels are ... coverage of these two events helped to resolve many ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a ... chosen as one of 18 "Showcase Companies" representing ... at the annual CED Tech Venture Conference on September ... Convention Center in Raleigh, North Carolina ... will lead a discussion during the "Digital Health Spotlight ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... 1, 2011 Tiny marine organisms called zooplankton can use ... areas of the ocean where oxygen levels are so low ... trouble as these areas expand due to climate change. ... said University of Rhode Island doctoral student Leanne Elder. "But ...
... 2011 (Bronx, NY) A longstanding medical mystery ... other cognitive problems despite potent antiretroviral therapy may have ... of Yeshiva University. Their findings are published in the June ... Even though antiretroviral treatment suppresses HIV replication and slows ...
... study co-authored by University of Florida researchers provides details on ... concern as warm summer waters attract more people to the ... July print edition of Pacific Science warns that ... may be considered prey. The sharks feed near ...
Cached Biology News:Climate change could turn oxygen-free seas from blessing to curse for zooplankton 2New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3
...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
... NPY Y2 Receptor antiserum This NPY ... spinal level and is currently being characerized in ... rat and mouse and appears to work better ... in rat. For full characterizarion in dorsal root ...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: